The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary.
 
John H. Farley
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
 
William E Brady
No Relationships to Disclose
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; MSD; Pfizer
Research Funding - Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Hiroyuki Nomura
No Relationships to Disclose
 
Mayu Yunokawa
No Relationships to Disclose
 
Hideki Tokunaga
No Relationships to Disclose
 
Motoaki Saitou
No Relationships to Disclose
 
David Marc Gershenson
No Relationships to Disclose